Category: Other

A total of four new pipeline products will launch, each of which of will have a higher annual cost of therapy (ACOT) when compared with the cost of the most used analgesics, which are highly genericized. The prospect of a disease-modifying therapy will also be welcomed for patients as the underlying pathophysiology of DNP will be targeted, rather than just being a symptomatic treatment. https://www.globaldata.com/store/report/diabetic-neuropathic-pain-market-analysis/